Swiftsure International Inc.
Holmes Biopharma, Inc.: Clinical Research Business Becomes Profitable

Holmes Biopharma Inc. / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Holmes Biopharma – Clinical Research Business Becomes Profitable

Scottsdale, Arizona – June 11, 2007 – Holmes Biopharma, Inc. (Symbol HHJA,
security code A0KDRX) is pleased to announce that it’s majority owned
subsidiary, Qualia Clinical Services Inc. ('Qualia') had its first
profitable month of operations in May/07.  Based on contracts committed at
this time, sales will exceed $1 million dollars in June/07 and sales growth
is expected to continue throughout the balance of 2007 and 2008.

'We are extremely pleased with the progress of Qualia, from startup to
profitability in just 7 months.  We have every reason to believe this
growth trend will continue as we add capacity in Omaha and other new
facilities this year', stated John Metcalfe, President of Holmes Biopharma
Inc.

About Holmes:
Holmes Biopharma Inc. is a contract research organization focused on
providing integrated and cost effective clinical development services that
help the pharmaceutical industry introduce new drug products rapidly from
laboratory to the market. For more information about the company please
visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors 

John F. Metcalfe, President

Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All information
contained in this press release should be independently investigated. This
press release contains forward-looking statements. These remarks involve
risks and uncertainties.  Risks are not limited to quarterly fluctuations
in results or the companies’ management of growth and competition. Other
risks are detailed in the Company's SEC filings.  Actual results may differ
materially from such information set forth herein.

Contact:
Investor Relations
Holmes Biopharma Inc. 
8655 East Via De Ventura, G-200, Scottsdale AZ 85258
Tel: 001-866-694-2803 
www.holmesbiopharma.com





DGAP 11.06.2007 
----------------------------------------------------------------------